Skip to main content
. 2024 Jun 4;19(6):e0300033. doi: 10.1371/journal.pone.0300033

Table 1. Characteristics of households and children and adolescents living with HIV and receiving care in a rural hospital in Macha, Zambia, overall and by level of food insecurity.

Overall
(n = 182)
Food secure or mildly food insecure
(n = 53)
Moderately or severely food insecure
(n = 129)
p-value
Demographic characteristics
Socioeconomic status, n (%) a,b 0.007
    Quartile 1 (lowest) 103 (57.2) 21 (40.4) 82 (64.1)
    Quartile 2 59 (32.8) 23 (44.2) 36 (28.1)
    Quartile 3 16 (8.9) 6 (11.5) 10 (7.8)
    Quartile 4 (highest) 2 (1.1) 2 (3.9) 0
Caregiver’s highest level of education, n (%) a 0.01
    None/primary 103 (71.4) 23 (44.2) 80 (62.5)
    Secondary 50 (27.8) 15 (28.9) 35 (27.3)
    College/Certificate 27 (15.0) 14 (26.9) 13 (10.2)
Age in years, median (25th, 75th percentiles) 13.7 (10.5, 17.7) 15.5 (11.1, 19.1) 13.4 (10.1 16.6) 0.17
Sex, n (%) 0.80
    Male 92 (50.5) 26 (49.1) 66 (51.2)
    Female 90 (49.5) 27 (50.9) 63 (48.8)
Parent’s vital status, n (%) 0.49
    Both alive 130 (71.4) 35 (66.0) 95 (73.6)
    One parent died 40 (22.0) 13 (24.) 27 (20.9)
    Both died 12 (6.6) 5 (9.4) 7 (5.4)
Nutritional, immunologic, virologic and treatment characteristics
Underweight / thin, n (%) c 21 (14.3) 4 (10.0) 17 (15.9) 0.36
Time on ART in years, median (25th, 75th percentiles) 9.0 (6.8, 11.5) 9.7 (6.9, 12.1) 8.8 (6.8, 11.3) 0.27
CD4+ T-cell count in cells/mm3, median (25th, 75th percentiles) d 803 (615, 1078) 736 (548, 1060) 818 (622, 1093) 0.57
CD4+ T-cell <500 cells/mm3, n (%) d 17 (14.7) 6 (18.8) 11 (13.1) 0.44
HIV viral load <50 copies/mL, n (%) e 118 (80.3) 37 (84.1) 81 (78.6) 0.45
HIV viral load <1000 copies/mL, n (%) e 138 (93.9) 42 (95.5) 96 (93.2) 0.60
Adherence ≤95%, n (%) f 35 (27.8) 10 (24.4) 25 (29.4) 0.56
ART regimen, n (%) 0.29
    ABC/3TC/DTG 20 (11.0) 4 (7.6) 16 (12.4)
    ABC/3TC/EFV 1 (0.6) 0 1 (0.8)
    ABC/3TC/LPVR 18 (9.9) 8 (15.1) 10 (7.8)
    AZT/3TC/DTG 2 (1.1) 1 (1.9) 1 (0.8)
    AZT/3TC/LPVR 16 (8.8) 2 (3.8) 14 (10.9)
    TAF/FTC/DTG 34 (18.7) 9 (17.0) 25 (19.4)
    TDF/3TC/DTG 81 (44.5) 24 (45.3) 57 (44.2)
    TDF/3TC/EFV 1 (0.6) 1 (1.9) 0
    TDF/FTC/DTG 1 (0.6) 0 1 (0.8)
    TDF/FTC/EFV 7 (3.9) 4 (7.6) 3 (2.3)
    TDF/FTC/LPVR 1 (0.6) 0 1 (0.8)

3TC: lamivudine; ABC: abacavir; ART: antiretroviral therapy; AZT: zidovudine; DTG: dolutegravir; EFV: efavirenz; FTC: emtricitabine; LPVR: lopinovir/ritonavir; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate

a Measured at enrollment into the cohort; all other characteristics measured at study visit where HFIAS and HWISE modules were administered [median = 10.2 years (25th, 75th percentiles: 6.9, 12.0) after enrollment]

b Based on socioeconomic status scale derived from data on housing characteristics, drinking water source, energy used for cooking, and asset ownership [20]; grouped into quartiles corresponding to scores of 0–6 (quartile 1; lowest), 7–12 (quartile 2), 13–18 (quartile 3), and 19–24 (quartile 4; highest)

c Underweight defined by weight-for-age Z score <-2 for children <5 years of age; thin defined by body mass index-for-age Z score <-2 for children and adolescents ≥5 years of age

d CD4 only available for 116 participants (63.7%); closest measure within 12 months prior the study visit was used [median = 182 days (25th, 75th percentiles: 0, 266) from measurement to study visit]

e HIV viral load only available for 147 participants (80.8%); closest measure within 12 months prior the study visit was used [median = 84 days (25th, 75th percentiles: 0, 182) from measurement to study visit]

f Adherence only available for 126 participants (69.2%); measured by pill count and defined based on the lowest measure for all drugs counted at the study visit